Co-Founder and CEO Alex Aravanis discusses the need for improved treatments in the obesity space and why he thinks Moonwalk's RNAi platform is an ideal approach.

Co-Founders Austin Draycott and Cole Lewis, describe the type of work they are doing (the co-lead programs target hepatocellular carcinoma and colorectal cancer) and the investors that participated in the financing, which include 4BIO Capital, AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund.

CEO Johannes Doll describes what he believes are the advantages of an inhaled sedative vs the traditional IV. The company already has experience commercializing this in Europe, with 1 out of 7 ICU patients in Germany currently using it. The U.S. PDUFA date is April 16.

CEO Martin Welschof walks us through recent ASCO (ovarian in combo with Keytruda) and EHA (CTLC) data for BI-1808, and describes why the company believes TNFR2 is a compelling checkpoint with wide applicability. Plus, BI-1206 (FcyRIIB), which will have NCSLC data later this year and BioInvent ultimately hopes to partner.

CEO Nikolaj Sørensen walks us through all the potential benefits of delivering medicines via a nasal spray, would theoretically could even include the ability to cross the BBB for CNS conditions. Naloxone and epinephrine are the most advance, and Oroxo also has plans for a nasal spray GLP and vaccines.

CEO Renée Aguiar-Lucander describes the idea behind imlifidase and discusses the trial that led to the U.S. filing. Hansa has also recently confidentially filed for an IPO in the United States as well.

CEO Erik Manting describes vididencel and the progress the company has been making in AML, CML, and ovarian cancer. Additional CML data is expected in this second half of the year.

Co-Founder & CEO Erik Wiklund highlights the potential of circular RNA and walks us through the work Circio is doing in gene and cell therapy, including heart and eye indications, CNS, and in vivo CAR-T. The company has raised approximately $65M USD this year, putting at the top of European biotech raises.

CEO Gunilla Osswald talks about the recently approved self-administered subcu formulation of lecanemab, called IQLIK, and updates us on a Parkinson's program that is moving along. Plus, how BioArctic's transferrin based brain transporter technology is different than others, which has resulted in numerous prestigious pharma partnerships.

Co-Founder and CEO Pete Smith describes how Remix uses small molecules to stop the transcription of disease causing mRNAs. The lead program targets MYB and is in a phase 1/2 for adenoid cystic carcinoma. The reverse merger could close towards the end of year.

CEO Amber Salzman discusses the benefit of the raise, and contrasts the funding environment in biotech today versus previous years. Plus, she describes the unmet need in FSHD and how AI has already been helping the company understand the patient experience in its current clinical trial.

Co-Founder, President & CEO Greg Verdine describes the toxicity issues associated with the immuosupressive drugs that transplant recipients currently receive, and explains how LIFE-001 is different. Plus, given how the therapy is designed to safely prevent T-cell activation and proliferation, there could also ultimately be an autoimmune use case as well.

CEO Ron Alfa describes the platform's design, and walks us through partnerships with Agenus and GSK.

Founder & CEO Errik Anderson describes the company's capabilities today and highlights a recent detail to help Voro Therapeutics develop masked T-cell engagers as an example of Alloy's broad capabilities.

He describes why Manifold is focused on in vivo work, even to the extent that it is trying to develop a 'virtual organism'. Plus, an update on the brain shuttle program that is partnered with Roche (it is not a transferrin program), and he explains the Anthropic news.

Co-Founder and CEO Surge Biswas walks us through the platform and describes the type of work that Nabla is doing for partners. Currently, it already has struck deals with Bristol, Astra, and Takeda (twice).

CEO Christian Rohlff describes the types of programs Oxford will be collaborating with these companies on, and discussed why the company has prioritized partnerships over an internal pipeline lately. Plus, details on a unique database the company has derived that could lead to even further programs and deals.

CEO Iain Kilty talks about Sitryx's approach to modulating inflammation and shares updates on the Boehringer deal, a program that has been received back from Lilly, and the company's clinical activities.

CEO Michalis Papadakis describes the technology and how it has the potential to greatly increase the number of people who experience stroke, and more quickly. The platform is FDA-cleared and CE-marked in Europe, and in wide use in Europe today. The company is also working on a lung fibrosis diagnostic.

CEO Mohit Rawat discusses the deal and the scientific rationale for N-myristoyltransferase inhibitor (NMTi) payloads.